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ABSTRACT 
Ascites is an accumulation of fluid in the peritoneal space and one of the first signs of 
decompensation of liver disease. Ascites is one of the complications experienced by patients with 
hepatic cirrhosis. Therapy commonly used for ascites is diuretics, along with salt restriction in the 
diet. Potassium-sparing diuretics, especially spironolactone and loop diuretics, especially 
furosemide, are the main pharmacological therapies for ascites. The purpose of this study was to 
examine the characteristics distribution of hepatic cirrhosis patients, to assess the profile of the use 
of diuretic drugs during hospitalization, and to determine the possibility of a Drug Related 
Problem (DRP) on diuretic therapy for patients with ascites at Airlangga University Hospital 
(RSUA) Surabaya. The research was conducted with non-experimental methods or observations, 
it was subsequently analyzed descriptively. Data collection was carried out in non-random and 
time limited sampling in the period of 1 January 2013 - 31 March 2017 in the Inpatient Room of 
Internal Medicine Department at RSUA Surabaya and was declared as ethically feasible. Based on 
the results of 45 SH samples with complications of ascites, the most common characteristics of 
hepatic cirrhosis patients were men by 53.33%, the highest age range was 45-64 years at 75.56%, 
while the highest complication was hypoalbumin with the percentage of 26.67% and the longest 
treatment duration was 6-10 days at 46.67%.The therapeutic profile of diuretics in this study, 
namely the use of furosemide as a single therapy with the percentage of 17.78% and single 
spironolactone therapy of 2.22% and combination therapy of spironolactone with furosemide with 
the percentage of 80.00 %. The most widely used furosemide was intravenous use with a daily 
dose of 1x20mg 57.78%, while spironolactone was the most widely used in oral use with a daily 
dose of 1x100mg 44.44%. Drug Related Problems (DRP) that occuedr including potential drug 
interactions found in concomitant use between spironolactone and potassium preparations with the 
percentage of 24.44%. No actual drug interactions and side effects were found in this study. 
Keywords: Hepatic Cirrhosis, Ascites, Diuretics, Spironolactone, Furosemide. 
 
1. INTRODUCTION 
 Hepatic cirrhosis is the twelfth highest death cause in the world with a death rate of 
1,028,000 each year (WHO, 2013). According to the reports of government public hospitals in 
Indonesia, the average prevalence of hepatic cirrhosis is 3.5% of all patients treated at Internal 
Medicine Installation, or an average of 47.4% of all liver disease patients treated (PPHI, 2013). 
Based on the reports from some general hospitals in Indonesia, it can be seen that the prevalence 
of hepatic cirrhosis treated in the hospital is about 3.6-8.4% in Java and Sumatra, while in 
Sulawesi and Kalimantan is less than 1% (Kusumobroto, 2012). 
  The complications that can be occurred on cirrhosis patients include Ascites, 
variseal hemorrhage, and hepatic encephalopathy (Dipiro et al, 2015). The complications emerge 
due to Ascites are spontaneous bacterial peritonitis, hepatorenal syndrome and dilutional 
hyponatremia (Tasnem et al, 2015). Ascites is the most common complication experienced by 
cirrhosis patients (Cesario et al, 2013). Approximately, 50% of hepatic cirrhosis patients 
experience the complication of Ascites in the last 10 years and the risk of mortality in cirrhosis 
patients with complications of Ascites increased by 50% in 3 years (Padersen et al, 2015). The 
common therapy used for Ascites is diuretics. The administration of diuretics is usually carried 
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out on 90% patients with Ascites especially Ascites grade 3 or 4. Diuretics therapy is carried out 
with salt restriction in the diet (Kusumobroto, 2012). 
 Increased aldosterone plays a role in Na retention and can develop into Ascites. Drugs that 
can inhibit the effects of aldosterone are rational treatments for Ascites. Spironolactone is the 
diuretics commonly used in Ascites therapy. This drug is more suggested because it works slowly 
and has potassium-sparing effect. Diuretics effect from spironolactone can be seen after 48 hours 
(Paldosky and Isselbacher, 2000). The indication of minimum effective dose of spironolactone can 
be obtained by observing the electrolyte concentration of the urine in order to determine the 
increased level of Sodium and the decreased Kalium that represent the effective competitive 
problems on aldosterone. In contrast, the development of hyperkalemia might cause the dose of 
spironolactone should be limited or reduced (Paldosky and Isselbacher, 2000). 
 Spironolactone and furosemide are the main pharmacological therapy for Ascites. The 
therapy commonly used is the polytherapy of 100 mg spironolactone and 40 mg furosemide given 
in the morning (Runyon, B. A., 2012). Patients with mild to moderate Ascites can be treated by 
using spironolactone 100-200 mg/day. If the therapy of spironolactone for two weeks does not 
give any good response, then furosemide should be added with the initial dose of 20-40 mg/day. I 
needed, the dose of spironolactone can be increased gradually up to 400 mg/day and the dose of 
furosemide can be increased gradually up to 160 mg/day (Biecker, 2011). If the restriction of 
sodium and the administration of high dose-diuretics do not give any positive response as in 
refractory Ascites, then it is allowed to perform Large Volume Parascentesis (LVP), Transjugular 
Intrahepatic Portosystemic Shunt (TIPS), and liver transplantation (Biecker, 2011). 
 NSAID drugs reduce kidney response to loop diuretics such as furosemide, by inhibiting 
the formation of prostaglandins so that the vasodilator effect of diuretics will decrease, there can 
be a decrease in natriuresis, sodium retention and hypervolemia (Archer1 et al, 2015). ACE-
Inhibitor drugs (captopril, enalapril) and Angiotensin Receptor Blocker drugs (losartan, 
telmisartan) can be additive if they are used simultaneously with potassium sparing diuretics, such 
as spironolactone, so it can increase the risk of hyperkalemia, cardiac arrhythmia, and cardiac 
arrest (Archer2 et al, 2015). The side effects of the use of furosemide include hypokalemia with 
metabolic alkalosis, hyponatraemia, hypomagnesaemia, and hyperuricemia (Harlan, E. Ives, 
2012). The side effects of the use of spironolactone include hyperkalemia, gynecomastia, gastritis, 
and gastrointestinal disorders such as nausea and vomiting (Archer2 et al, 2015). 
 
2. METHODS 
This study was conducted by using non-experimental or observational method that was 
retrospective descriptive through patient medical records. All hepatic cirrhosis patients 
hospitalized in RSUA became the population and some of the population that fulfilled the 
inclusion criteria i.e. hepatic cirrhosis patients with Ascites that are given diuretics therapy and 
hospitalized in RSUA on January 2013 up to March 2017 became the sample of the research. 
 Patients fulfilled the inclusion criteria as the sample of the study if they meet the criteria 
i.e. hepatic cirrhosis patients with Ascites complication, male or female ≥ 20 years old given 
diuretics therapy and the Health Medical record is complete including name, age, gender, therapy 
given, clinical data and laboratory data. The patients that were hospitalized in RSUA less than 
three days cannot be the sample of the study. 
 The sampling techniques was Time Limited Sampling, i.e. taking all data of the Health 
Medical record of the patients fulfilling the inclusion criteria on January 2013 – March 2017. The 
variable observed was the hepatic cirrhosis patients with Ascites, age, gender, type of drug, dose, 
route of use, frequency of administration, duration of use, clinical data (BP, pulse, temperature, 
RR, urine volume, weight, abdominal circumference), laboratory data on Electrolyte levels (Na, 
K, Cl), SGOT/AST, SGPT/ALT and Albumin. 
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3. RESULT 
In this study, the researcher collected the Health Medical record of the hepatic cirrhosis 
patients hospitalized in Internal Medicine polyclinic in Airlangga University Hospital (RSUA) 
Surabaya in the period of January 1 2013 – March 31 2017, and obtained the sample of the study 
as many as 157 patients. From the sample, it was obtained 45 patients fulfilled the inclusion 
criteria i.e. hepatic cirrhosis patients with Ascites given diuretics therapy. 
3.1. The Characteristics of the Research Subject 
The characteristics of this research subject are the gender, age, and the complication and 
the length of stay. Below is the characteristics of the 45 hepatic cirrhosis patients with Ascites 
fulfilled the inclusion criteria. 
3.1.1. Profile of Gender 
From the 45 hepatic cirrhosis with Ascites in the study, based on the gender of the patients, it 
was obtained 53.33% male hepatic cirrhosis patients with Ascites and 46.67% female hepatic 
cirrhosis patients with Ascites. The characteristics of the research subject according to the gender 
can be seen in Table 1. 
 
Table 1 The gender of the hepatic cirrhosis patients with Ascites 
No. Gender Amount of Patients 
Percentage 
(%) 
1. Male  24 53,33 
2. Female 21 46,67 
Total 45 100,00 
3.1.2 Profile of Age 
According to Ministry of Health of the Republic of Indonesia of 2010, the age range is 
classified into 4 classifications i.e. young adult (18-24 years old), middle-aged adults (25-44 years 
old), late adult (45-64 years old) and elderly (>65 years old). The distribution of the age of hepatic 
cirrhosis with Ascites can be seen in Table 2. The average of the age of hepatic cirrhosis patients 
in this study was 58 ± 10.20 years old. The most hepatic cirrhosis with Ascites in this study was 
the age range of 45-64 years old 75.56%. 
Table 2 The distribution of the age of hepatic cirrhosis patients with Ascites 
No. Age Range Amount of Patients 
Percentage 
(%) 
1. 18-24 years old 0 0,00 
2. 25-44 years old 1 2,22 
3. 45-64 years old 34 75,56 
4. ≥65 years old 10 22,22 
Total 45 100,00 
3.1.3 Profile of the Complication of Hepatic Cirrhosis 
In this study, hepatic cirrhosis patients came with several kinds of complications. The three 
most common complications experienced by hepatic cirrhosis patients are Hypoalbumin 26.67%, 
Anemia 24.44%, and Spontaneous Bacterial Peritonitis (SBP) 20.00%. Other complications 
experienced by hepatic cirrhosis patients with Ascites can be seen in Table 3. 
Table 3 The complication of hepatic cirrhosis patients with Ascites when being 
hospitalized  
Complication Amount of Patients  
Percentage 
(%) 
Hypoalbumin 12 26,67 
Anemia 11 24,44 
Spontaneous Bacterial Peritonitis 9 20,00 
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(SBP) 
Hematemesis-Melena (HM) 8 17,78 
Melena 7 15,56 
Hepatic Encephalopathy (EH) 4 8,89 
Obstructive jaundice 1 2,22 
Information: One patient can experience more than one complication 
3.1.4 Profile of the Length of Stay in Hospital 
The length of stay of the patients in hospital is calculated since the patients are hospitalized 
until they are discharged from the hospital. The average length of stay was 8 ± 4.81 days. The 
most hepatic cirrhosis patients with Ascites in this study belonged to the duration of 6-10 days i.e. 
46.67%. The length of stay of the patients can be seen in Table 4. 
Table 4 The length of stay in hospital 
Length of 
Stay  
Amount of 
Patients 
Percentage 
(%) 
3-5 days 15 33,33 
6-10 days 21 46,67 
>10 days 9 20,00 
Total 45 100,00 
Information: 
1. Percentage was calculated from the whole sample of patients 
2. One patient might be hospitalized more than once. 
3.2. The Design of the Use of Diuretics 
3.2.1 The Type of Diuretics 
The diuretics given to hepatic cirrhosis patients with Ascites in this study were classified 
based on the class and type of diuretics that can be seen in Table 5. The diuretics mostly used on 
hepatic cirrhosis patients with Ascites in this study was loop diuretics i.e. furosemide 86.67%, 
then followed by potassium sparing diuretics i.e. spironolactone 62.22%. 
Table 5 The type of diuretics used on hepatic cirrhosis patients with Ascites 
Diuretics Amount of Patients 
Percentage of Use 
(%) 
Class Type   
Potassium sparing diuretics Spironolactone 1 222 
Loop diuretics Furosemide 8 17.78 
Potassium sparing diuretics + Loop 
diuretics 
Spironolactone 
+ Furosemide 36 80.00 
Total 45 100.00 
Information: 
The percentage was calculated based on the amount of hepatic cirrhosis patients with Ascites 
given diuretics i.e. 45 patients, seen on the whole use of diuretics.  
3.2.2 The Diuretic Regimentation 
Various types of diuretics given to hepatic cirrhosis patients with Ascites in this study were 
classified based on the dose, route, and frequency of use that can be seen in Table 6. In this study, 
the diuretics mostly used was spironolactone (1x100 mg) orally on 57.78% then followed by 
furosemide diuretics (1x20 mg) IV on 44.44%. 
Table 6 The route, dose, and frequency of diuretics used by the patients 
The Name of 
Drugs 
Dose and 
Frequency Route 
Amount of 
Patients 
Percentage 
(%) 
Spironolactone 1x100 mg orally 20 44.44 3x25 mg Orally 7 15.56 
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3x50 mg orally 4 8.89 
1x25 mg orally 3 6.67 
1x50 mg orally 2 4.44 
3x100 mg orally 2 4.44 
2x25 mg orally 1 2.22 
2x100 mg orally 1 2.22 
1x100 mg IV 1 2.22 
Furosemide 
1x20 mg IV 26 57.78 
2x20 mg IV 12 26.67 
3x20 mg IV 11 24.44 
1x40 mg orally 2 4.44 
2x40 mg orally 1 2.22 
4x20 mg IV 1 2.22 
3x40 mg IV 1 2.22 
Information: 
The percentage was calculated based on the amount of hepatic cirrhosis patients with Ascites 
given diuretics i.e. 45 patients, seen on the whole use of diuretics.  
 In this study, the dose of spironolactone and furosemide diuretics was presented in this 
following Table 7: 
Table 7 The monotherapy and polytherapy used by the patients 
The Types 
of Therapy 
Class of 
Diuretics The Name of Drugs 
Amount 
of 
Patients 
Percentage 
(%) 
Diuretics 
monotherapy 
Potassium 
Sparing 
Diuretics 
Spironolactone 100 mg 7 15.56 
Spironolactone 25 mg 1 2.22 
Spironolactone 200 mg 1 2.22 
Loop 
diuretics 
Furosemide 20 mg 11 24.44 
Furosemide 60 mg 5 11.11 
Furosemide 40 mg 4 8.89 
Furosemide 80 mg 1 2.22 
Polytherapy 
Potassium 
Sparing 
Diuretics + 
Loop 
Diuretics 
Spironolactone 100 mg – Furosemide 
40 mg 11 24.44 
Spironolactone 100 mg – Furosemide 
20 mg 9 20.00 
Spironolactone 100 mg – Furosemide 
60 mg 8 17.78 
Spironolactone 75 mg – Furosemide 
20 mg 7 15.56 
Spironolactone 200 mg – Furosemide 
40 mg 4 8.89 
Spironolactone 25 mg – Furosemide 
40 mg 
2 4.44 
Spironolactone 50 mg – Furosemide 
20 mg 
2 4.44 
Spironolactone 50 mg – Furosemide 
40 mg 
2 4.44 
Spironolactone 200 mg – Furosemide 
60 mg 
2 4.44 
Spironolactone 25 mg – Furosemide 1 2.22 
 
 
The 6th Asian Academic Society International Conference (AASIC) 
A Transformative Community: 
Asia in Dynamism, Innovation, and Globalization 
         
©Copyright 2018 proceeding of the 6th AASIC      36 
 
 
20 mg 
Spironolactone 50 mg – Furosemide 
60 mg 
1 2.22 
Spironolactone 100 mg – Furosemide 
120 mg 
1 2.22 
Spironolactone 300 mg – Furosemide 
40 mg 
1 2.22 
Spironolactone 300 mg – Furosemide 
60 mg 
1 2.22 
Information: 
1. The percentage was calculated based on the amount of hepatic cirrhosis patients with Ascites 
given diuretics i.e. 45 patients. 
2. One patient might be given more than one diuretics. 
3.2.3 Profile of Drugs Therapy Other Than Diuretics 
Hepatic cirrhosis patients with Ascites in this study were not only given diuretics therapy but 
also given drugs used to prevent and overcome hepatic cirrhosis complications used by the 
patients hospitalized in RSUA Surabaya. The use of drugs other than diuretics can be seen in 
Table 8. Three uses of drugs other than diuretic received by hepatic cirrhosis patients with Ascites 
are mostly 20% albumin infusion 93.33%, omeprazole 73.33%, and cefotaxime 60.00%. 
Table 8 The drugs therapy other than diuretics 
No. Complication  Drugs therapy Amount of Patients 
Persentase 
(%) 
1.  Hypoalbumin  Albumin 20%  42 93.33 
2. Anemia  
Thrombocytopenia 
Transfusion 
PRC  
TC  
21 
1 
46.67 
2.22 
3. Hypokalemia  KCl premix  2 4.44 
  KSR  9 20.00 
4.  Portal hypertension Propanolol 14 31.11 
5.  Antibiotics for 
Spontaneous Bacterial 
Peritonitis  
(SBP) therapy or 
sepsis 
Cefotaxime  
Ceftriaxone  
Levofloxacin  
Ceftazidim  
Ciprofloxacin  
Cefixime  
27 
7 
1 
1 
5 
1 
60.00 
15.56 
2.22 
2.22 
11.11 
2.22 
6.  Hepatic 
Encephalopathy (HE)  
Lactulose  
Comafusin 
Hepar  
20 
1 
44.44 
2.22 
  Metronidazole  1 2.22 
7.  Variseal hemorrhage 
or Melena 
hematemesis  
Omeprazole  
Ranitidine  
Sucralfat  
33 
9 
19 
73.33 
20.00 
42.22 
  Vitamin K  11 24.00 
  Lansoprazole  1 2.22 
  Octreotide   1 2.22 
Information: 
1. One patient might use more than one co-therapy. 
2. The percentage was calculated based on the amount of hepatic cirrhosis patients with 
Ascites given diuretics i.e. 45 patients. 
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3.3 The Identification of Drug Related Problems (DRP) 
Hepatic cirrhosis patients with Ascites in this study were also given drug therapy other than 
diuretics for the complication or co-morbidity experienced by the patients. That makes the patients 
given a lot of drug therapies, so that patients are susceptible to DRP. The problems related to the 
use of diuretics on hepatic cirrhosis patients with Ascites in this study include potential drug 
interactions. From the 45 hepatic cirrhosis patients with Ascites who received diuretics, 24.44% of 
them were with potential drug interactions that can be seen in Table 9 
Table V.9 Potential drug interaction 
Types of DRP Information 
Monitoring 
Parameter 
Amount 
of 
Patients 
Percentage 
(%) 
Spironolactone with 
Potassium Preparations 
(KCl or KSR) 
Potassium Preparation 
increases the risk of 
hyperkalemia  
Serum 
potassium 
level 
11  24,44 
 
4 CONCLUSIONS 
The hepatic cirrhosis patients with Ascites are mostly male 53.33%, in the age of 58 ± 10,20 
years old with the most age range is 45-65 years old 75.56%. The most common complication 
experienced is Hypoalbumin, 26.67%. The most common length of stay is 6-10 days i.e. 46.67%. 
The diuretics commonly used are furosemide polytherapy of spironolactone and furosemide 
80.00%. DRP found in this study is potential drug interaction due to the simultaneous use of 
spironolactone and potassium preparation. 
 
5 SUGGESTION 
1. It suggests further study using prospective method in order to understand the condition of 
patients directly and the problems occurred during the diuretics treatment and be able to 
directly interact with clinicians and other health workers so complete data can be obtained. 
2. It suggest to record the complete health medical record of the patients so monitoring can be 
performed and it can be used as the source of information for the evaluation to improve 
hospital services. 
3. It suggests a cooperation between physicians, pharmacists and other health workers in 
optimizing the use of diuretics especially to prevent the development of diuretics resistance 
and improving the services to the patients.  
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